Analysts See $-1.30 EPS for Catalyst Biosciences, Inc. (CBIO); Shorts at DANONE SPONSORED ADR FRANCE (DANOY) Raised By 22.42%

April 20, 2018 - By Kurt Siggers

Danone SA (OTCMKTS:DANOY) Logo

Analysts expect Catalyst Biosciences, Inc. (NASDAQ:CBIO) to report $-1.30 EPS on May, 10.They anticipate $3.27 EPS change or 71.55% from last quarter’s $-4.57 EPS. After having $-0.96 EPS previously, Catalyst Biosciences, Inc.’s analysts see 35.42% EPS growth. The stock decreased 3.76% or $1.0635 during the last trading session, reaching $27.2165. About 70,113 shares traded. Catalyst Biosciences, Inc. (NASDAQ:CBIO) has risen 405.24% since April 20, 2017 and is uptrending. It has outperformed by 393.69% the S&P500.

DANONE SPONSORED ADR FRANCE (OTCMKTS:DANOY) had an increase of 22.42% in short interest. DANOY’s SI was 489,300 shares in April as released by FINRA. Its up 22.42% from 399,700 shares previously. With 648,900 avg volume, 1 days are for DANONE SPONSORED ADR FRANCE (OTCMKTS:DANOY)’s short sellers to cover DANOY’s short positions. The SI to DANONE SPONSORED ADR FRANCE’s float is 0.02%. The stock decreased 1.21% or $0.2 during the last trading session, reaching $16.31. About 169,468 shares traded. Danone SA (OTCMKTS:DANOY) has 0.00% since April 20, 2017 and is . It has underperformed by 11.55% the S&P500.

Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. The company has market cap of $323.70 million. The Company’s product pipeline includes marzeptacog alfa, a Factor VIIa variant that completed a Phase I clinical trials evaluating safety, tolerability, pharmacokinetics, pharmacodynamics, and coagulation activity in severe hemophilia A and B patients with inhibitors. It currently has negative earnings. The firm also develops CB 2679d/ISU304, a Factor IX drug, which has completed preclinical studies for the prophylactic treatment of individuals with hemophilia B; and CB 2782, a pre-clinical anti-C3 protease program for the treatment of dry age-related macular degeneration.

Among 5 analysts covering Danone SA (OTCMKTS:DANOY), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Danone SA had 5 analyst reports since September 2, 2015 according to SRatingsIntel. Bernstein initiated Danone SA (OTCMKTS:DANOY) on Monday, October 3 with “Outperform” rating. The stock of Danone SA (OTCMKTS:DANOY) has “Buy” rating given on Thursday, November 19 by Societe Generale. HSBC initiated the shares of DANOY in report on Wednesday, January 6 with “Buy” rating. The rating was downgraded by Davy Research on Thursday, February 9 to “Neutral”. The firm has “Hold” rating by Zacks given on Wednesday, September 2.

Danone operates as a food company worldwide. The company has market cap of $51.25 billion. The Company’s Fresh Dairy Products division produces and markets yogurts, fermented fresh dairy products, and specialized dairy products under the Oikos, Danio, Activia, Danonino, Fruchtswerge, Danoninho, Danimals, Serenito, Tëma, Actimel, Danacol, Densia, Danette, Fantasia, Danissimo, YoCrunch, Vitalinea, Light & Fit, Taillefine, and Ser brands. It has a 17.03 P/E ratio. The companyÂ’s Waters division offers packaged natural, flavored, and vitamin-enriched water under the evian, Volvic, Badoit, Aqua, Mizone, Bonafont, Villavicencio, Villa del Sur, Fontvella, Lanjarón, and Zywiec Zdroj brands.

Catalyst Biosciences, Inc. (NASDAQ:CBIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts